The press service of the agency informs about it.
It is noted that the unique set of reagents "AmpliTest SARS-CoV-2 VOC v.2" was developed by scientists of the Center for Strategic Planning and Management of Medical and Biological Health Risks of the FMBA to detect the RNA of the SARS-CoV-2 coronavirus of the Alfa, Beta / Gamma and Delta genetic lines based on the determination of their characteristic mutations in the S-protein of the virus by the method of polymerase chain reaction.
The kit was registered on July 21, it was introduced into production and is ready for serial production.
Earlier, FMBA began clinical trials of its coronavirus vaccine.
As of July 22, 24,471 cases of coronavirus infection were registered in Russia per day.
In total, 6,054,711 patients with COVID-19 were identified in the country during the pandemic.
Doctor Timur Pesterev, in an interview with FAN, gave advice on vaccination against COVID-19.